Edgewise Therapeutics Shares Higher on Positive Trial Results

Dow Jones

Dec 16, 2024

By Dean Seal

Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy.

The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year.

The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage.

Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 16, 2024 09:38 ET (14:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491692522"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491692522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491692522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491692522","market":"fut","top_or_hot":-1,"title":"Edgewise Therapeutics Shares Higher on Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. \n</p>\n<p>\n  The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year. \n</p>\n<p>\n  The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage. \n</p>\n<p>\n  Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 09:38 ET (14:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Shares Higher on Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Shares Higher on Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-16 22:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. \n</p>\n<p>\n  The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year. \n</p>\n<p>\n  The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage. \n</p>\n<p>\n  Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 09:38 ET (14:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491692522","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491692522","pubTimestamp":1734359880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy.The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year.The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage.Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","EWTX":"Edgewise Therapeutics, Inc.","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Edgewise Therapeutics股价因积极的试验结果而走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1,"LENZ":1},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. \n\n\n  The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year. \n\n\n  The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage. \n\n\n  Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 09:38 ET (14:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}